CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
复制标题
DOI：
10.1093/annonc/mdn392
复制
发表时间：
2008-11-01
影响因子：
50.5
通讯作者：
Hatake, K.
中科院分区：
文献类型：
--
作者：
Ennishi, D.;Takeuchi, K.;Hatake, K.
背景资料：在接受利妥昔单抗联合化疗治疗弥漫性大B细胞淋巴瘤（DLBCL）的患者中，已经重新评估了几种指示预后不良的生物标志物。然而，很少有研究调查与这些生物标志物的组合有关的结果。此外，没有大规模的研究已经重新评估了与利妥昔单抗治疗的CD 5阳性DLBCL患者的结果。患者和方法：我们进行了一项回顾性研究，并调查了三个生物标志物的预测价值-BCL 2，生发中心（GC）表型和CD 5-在121例DLBCL患者与利妥昔单抗加环磷酰胺，多柔比星，长春新碱和泼尼松治疗。CD 5阳性患者的无事件生存率（EFS）和总生存率（OS）明显低于CD 5阴性患者（2年EFS，18%比73%，P < 0.001; 2年OS，45%比91%，P = 0.001）。然而，没有观察到根据BCL 2或GC表型的结果的显著差异。多因素分析显示，CD 5表达是EFS [危险比14.2，95%可信区间（CI）4.7-43.2]和OS（危险比20.3，95% CI 3.6-114.4）的重要预后因素。需要更多的研究来证实CD 5表达对接受含利妥昔单抗化疗的DLBCL患者的预后意义。
Background: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab.Patients and methods: We conducted a retrospective study and investigated the predictive value of three biomarkers-BCL2, germinal center (GC) phenotype and CD5-in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.Results: CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P < 0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4).Conclusions: CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.